Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

AbbVie Stock News

ABBVNYSE

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$189.83

2.361.26%

At close: -

$189.83

0.000.00%

After Hours: 4:20 PM EDT

AbbVie (ABBV) Forecast

News

Earnings AbbVie (ABBV) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest AbbVie Stock News | NYSE:ABBV | Benzinga

Get the latest news on AbbVie stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on AbbVie performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, June 04, 2025

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Vandana Singh
9 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights

Monday, June 02, 2025

Meta, JPMorgan, Gap And A Health Care Stock On CNBC's 'Final Trades'
Avi Kapoor

Friday, May 30, 2025

CNBC Halftime Report Final Trades: Meta Platf...
Benzinga Newsdesk

Wednesday, May 28, 2025

10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Sarah Cannon Research Institute Announces Str...
Benzinga Newsdesk

Tuesday, May 27, 2025

10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
AbbVie To Present Cancer Trial Data At Upcoming ASCO Event
Vandana Singh
AbbVie Says Key Data From Broad Oncology Port...
Benzinga Newsdesk

Tuesday, May 20, 2025

10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights

Friday, May 16, 2025

3 Stocks That Will Profit From Trump's Drug Price Cut
Nic Chahine

Thursday, May 15, 2025

Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
Sandeep Gupta
Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Bets
Shomik Sen Bhattacharjee

Wednesday, May 14, 2025

FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases
Vandana Singh
AbbVie shares are trading lower after Citigro...
Benzinga Newsdesk
AbbVie Announces That EMRELIS Has Been Grante...
Benzinga Newsdesk
Expert Outlook: AbbVie Through The Eyes Of 10 Analysts
Benzinga Insights
AbbVie And ADARx Pharma Announce Collaboratio...
Benzinga Newsdesk
Citigroup Downgrades AbbVie to Neutral, Lower...
Benzinga Newsdesk

Tuesday, May 13, 2025

A Look Into AbbVie Inc's Price Over Earnings
Benzinga Insights
What Does the Market Think About AbbVie?
Benzinga Insights

Monday, May 12, 2025

AbbVie Unusual Options Activity
Benzinga Insights
Congressional Trading Report: Rep. Jared Moskowitz Bought Over $27K In AbbVie Stock
Benzinga Insights
Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation
Piero Cingari

Friday, May 09, 2025

10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
Recent Report Shows That Rep. Jefferson Shreve Bought Up to $4.75M Worth of Apple Stock
Benzinga Insights

Wednesday, May 07, 2025

Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Chris Katje
This House of Representative Just Bought Up To $915K In AbbVie Stock
Benzinga Insights

Tuesday, May 06, 2025

Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns
Tanya Rawat

Monday, May 05, 2025

Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
Vandana Singh

Saturday, May 03, 2025

Benzinga Bulls And Bears: Lilly, Microsoft, Starbucks — And Markets Fully Recover Tariff Chaos Losses
Benzinga Senior Editor

Thursday, May 01, 2025

8 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights

Wednesday, April 30, 2025

Netflix, Sherwin-Williams, AbbVie And More On CNBC's 'Final Trades'
Avi Kapoor

Tuesday, April 29, 2025

AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis
Vandana Singh
CNBC Halftime Report Final Trades: Netflix, A...
Benzinga Newsdesk
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Benzinga Insights
Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next?
Mark Putrino
Guggenheim Maintains Buy on AbbVie, Raises Pr...
Benzinga Newsdesk
Abbvie: FDA Approves RINVOQ, 15 Mg, Once Dail...
Benzinga Newsdesk
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
Vishaal Sanjay

Monday, April 28, 2025

AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst
Vandana Singh
AbbVie's Options Frenzy: What You Need to Know
Benzinga Insights
AbbVie shares are trading higher after multip...
Benzinga Newsdesk
Evercore ISI Group Maintains Outperform on Ab...
Benzinga Newsdesk
Morgan Stanley Maintains Overweight on AbbVie...
Benzinga Newsdesk
US Stock Futures Fall As Markets Brace For Earnings From Microsoft, Meta, Apple And Apple This Week: 'Earnings Estimates Don't Signal A Recession' Says Leading Analyst
Vishaal Sanjay

Saturday, April 26, 2025

How Much Would It Take To Earn $100 A Month From AbbVie Stock
David Kirakosyan

Friday, April 25, 2025

Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday?
Piero Cingari
AbbVie Raises Profit Outlook But Flags Tariff Risks In Pharma Sector
Vandana Singh
AbbVie shares are trading higher after the co...
Benzinga Newsdesk

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved